{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=96", "query": { "condition": "Patient", "page": 96 }, "page_size": 10 }, "pagination": { "page": 96, "page_size": 10, "total_count": 54988, "total_pages": 5499, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=97&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient&page=95&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T03:48:00.904Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00425750", "title": "Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-08", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2011-11-16", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 7, "location_summary": "Hopkinsville, Kentucky • Paducah, Kentucky • Crossville, Tennessee + 3 more", "locations": [ { "city": "Hopkinsville", "state": "Kentucky" }, { "city": "Paducah", "state": "Kentucky" }, { "city": "Crossville", "state": "Tennessee" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00425750" }, { "nct_id": "NCT02587650", "title": "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ALK Fusion Protein Expression", "BRAF wt Allele", "Invasive Skin Melanoma", "MET Fusion Gene Positive", "NRAS wt Allele", "NTRK1 Fusion Positive", "NTRK2 Fusion Positive", "NTRK3 Fusion Positive", "RET Fusion Positive", "ROS1 Fusion Positive", "Stage III Cutaneous Melanoma", "Stage IIIA Cutaneous Melanoma", "Stage IIIB Cutaneous Melanoma", "Stage IIIC Cutaneous Melanoma", "Stage IV Cutaneous Melanoma" ], "interventions": [ { "name": "Capmatinib", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-03-26", "completion_date": "2018-07-12", "has_results": true, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02587650" }, { "nct_id": "NCT00006450", "title": "Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor" ], "interventions": [ { "name": "Phenylbutyrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 120, "start_date": "2000-11", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006450" }, { "nct_id": "NCT00081250", "title": "Creatine in Treating Patients With Cancer-Associated Weight Loss", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anorexia", "Cachexia", "Unspecified Adult Solid Tumor, Protocol Specific", "Weight Changes" ], "interventions": [ { "name": "creatine monohydrate", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2004-12", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2020-04-29", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 220, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 139 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081250" }, { "nct_id": "NCT04856891", "title": "A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Duodenitis", "Eosinophilic Gastroenteritis" ], "interventions": [ { "name": "AK002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 94, "start_date": "2021-05-20", "completion_date": "2023-01-09", "has_results": true, "last_update_posted_date": "2024-01-02", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Chula Vista, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Lomita", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04856891" }, { "nct_id": "NCT00848991", "title": "Comparison of Propofol to Precedex With Propofol for Emergence and Recovery in Patients Having Craniotomy Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cranitomy Surgery" ], "interventions": [ { "name": "Precedex", "type": "DRUG" }, { "name": "Propofol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cooper Norcross Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2009-02", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2012-02-10", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 1, "location_summary": "Camden, New Jersey", "locations": [ { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00848991" }, { "nct_id": "NCT01673191", "title": "A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Macular Edema", "Diabetes Mellitus" ], "interventions": [ { "name": "Dexamethasone intravitreal implant", "type": "DRUG" }, { "name": "Steroid plus NSAID eye drop combination therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Retinal Consultants of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2012-11", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01673191" }, { "nct_id": "NCT01015118", "title": "LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "BIBF 1120", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1366, "start_date": "2009-11-17", "completion_date": "2016-09-15", "has_results": true, "last_update_posted_date": "2017-12-07", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 33, "location_summary": "Tucson, Arizona • Long Beach, California • Santa Rosa, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01015118" }, { "nct_id": "NCT04432818", "title": "Digital Life Coaching for Myeloma Patients Undergoing Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pack Health's digital life coaching (DLC)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-05-20", "completion_date": "2021-02-25", "has_results": false, "last_update_posted_date": "2021-06-04", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04432818" }, { "nct_id": "NCT02391818", "title": "The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Distorted; Balance", "Quality of Life", "Neuropathy", "Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "OSF Healthcare System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 19, "start_date": "2015-02", "completion_date": "2017-06-16", "has_results": false, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-11-13T03:48:00.904Z", "location_count": 4, "location_summary": "Pekin, Illinois • Peoria, Illinois", "locations": [ { "city": "Pekin", "state": "Illinois" }, { "city": "Pekin", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02391818" } ] }